Hot Topics in Obesity Treatment - PowerPoint PPT Presentation

1 / 42
About This Presentation
Title:

Hot Topics in Obesity Treatment

Description:

Effect of Continuous and Intermittent Phentermine Therapy on Body Weight ... include: sibutramine, orlistat, phentermine, diethylpropion, fluoxetine and bupropion ... – PowerPoint PPT presentation

Number of Views:435
Avg rating:3.0/5.0
Slides: 43
Provided by: moulton5
Category:

less

Transcript and Presenter's Notes

Title: Hot Topics in Obesity Treatment


1
Hot Topics in Obesity Treatment
2
Prevalence of Overweight and Obesity Among US
Adults
(BMI ?25.0)
(BMI 25.0-29.9)
(BMI ?30.0)
Up 100 in 20 years
NHANES II1976-1980(n11,207)
NHANES 1999-2000(n3601)
NHANES III1988-1994(n14,468)
NHANESNational Health and Nutrition Examination
Survey. Age-adjusted by the direct method to the
year 2000 US Bureau of the Census estimates
using the age groups 20-34, 35-44, 45-54, 55-64,
and 65-74 years Flegal KM et al. JAMA.
20022881723-1727.
3
Binge Eating
  • Could there be a survival advantage to being able
    to binge or eat more in an environment with
    limited food?

4
Lateral Hypothalamic area
Pituitary Forebrain Adrenals
Paraventricular Nucleus
Feeding behavior Metabolic status save
calories burn calories
Y1-receptor
MC4R
Insulin Pancreas
POMC MSH
NPY
Leptin Adipose tissue
PYY Intestines
Ghrelin Stomach
5
Binge and MC4R Gene
  • Two articles in the NEJM March 2003
  • Branson 5.1 of obese had MC4R gene mutations
  • Farooqi 5.8 of obese had MC4R gene mutations
  • All mutation carriers reported binge eating

6
Binge Eating
  • 469 morbid obese Caucasian patients
  • 79 female
  • Found 24 pts (5.1) with a mutation of the MC4R
  • Basically a defective receptor
  • All 24 of these pts (100) had binge eating
  • Only 14 of matched controls had binging

NEJM 34812, 2003.
7
Binge Eating
  • 500 morbid obese children
  • Found 29 pts (5.8) with a mutation of the MC4R
  • Basically a defective receptor
  • All 29 of these patients had hyperphagia
  • Compared to unaffected siblings they ate three
    times as much food at a single meal
  • Meal size corrected for lean body mass

NEJM 34812, 2003.
8
Homozygous Mutation in Melanocortin-4 Receptor
Gene
Farooqi IS et al. N Engl J Med.
20033481085-1095.
9
MC4R Mutations
  • Mutations carriers were
  • Severely obese
  • Increased lean mass
  • Increased linear growth
  • Severe hyper-insulinemia
  • Homozygotes were more severely effected than
    heterozygotes

10
Binge Eating Disorder
Definition of a Binge Episode
  • Eating an amount of food that is definitely
    larger than most people would eat in similar
    circumstances during a similar period of time
    (eg, 2x a normal portion in 2 hours)
  • A sense of lack of control during the episodes
  • Sense of inability to stop or control eating
  • Marked distress about the binge eating
  • Women yes, men often not
  • Binge eating is a provisional DSM code at this
    time

11
Secondary Binge Criteria
  • Eat alone (closet eating)
  • Eat when not hungry
  • Eat fast
  • Eats until uncomfortably full
  • Feeling of guilt or un-happiness after eating
  • Loose criteria different for men and women

12
Questions for the Clinician to Ask Patients Who
Might Have Binge Eating Disorder
  • Do you ever have episodes of eating where you
    feel out of control or that you just could not
    stop yourself?
  • Do you ever eat large portions of food that would
    clearly be larger portions that other persons
    might eat in a similar circumstance?

13
Diagnostic Criteria for Bulimia Nervosa (BN)
  • Recurrent episodes of binge eating with loss of
    control
  • Recurrent inappropriate compensatory behavior to
    prevent weight gain
  • Binge eating and inappropriate compensatory
    behavior both occur, on average, at least twice a
    week for 3 months
  • Self-evaluation is unduly influenced by body
    shape and weight

14
Prevalence of BED in Community Samples
  • BED is found in 2 to 3 of adults
  • About half are obese

Bruce B, Agras WS. Int J Eat Disord.
199212365-373. Spitzer RL et al. Int J Eat
Disord. 199211191-203.
15
Prevalence of BED in Clinical Samples
  • BED in obese treatment seekers
  • 7.6 to 18.8 (rigorously defined)
  • 20 to 40 (broadly defined)
  • BED in Overeaters Anonymous 70
  • BED in bariatric surgery seekers 25 to 50

Stunkard AJ. In Handbook of Obesity Treatment.
2002. Wadden TA et al. Surg Clin N Am.
2001811001-1014. Williamson DA, Martin CK. Eat
Weight Disord. 19994103-114.
16
BED and Depression
Yanovski SZ, et al. Am J Psychiatry. 1993
1501472-1479.
17
Binge Eating and Overweight
Telch CF et al. Int J Eat Disord. 19887115-119.
18
Frequency of Binge Eating in BN
Fluoxetine Bulimia Nervosa Collaborative Study
Group. Arch Gen Psychiatry. 199249139-147.
19
Fluoxetine in BED
Mean Binges/Week
P 0.03
Arnold LM et al. J Clin Psychiatry.
2002631023-1028.
20
Sibutramine in BED
  • Placebo-controlled, randomized, double-blind
    trial
  • 15 mg/d
  • 4-week placebo run-in 6-month double-blind
    treatment
  • Placebo run-in n 549
  • Randomized n 304
  • Completed n 189
  • Baseline values determined after placebo run-in
  • Outcome measures
  • Binge frequency and weight
  • A significant difference from placebo was
    achieved for both outcomes

Wilfley DE et al. Presented at the Eating
Disorders Research Society Annual Meeting
Charleston, South Carolina November 20-22, 2002.
21
Sibutramine in BED
Binge Days Per Week
Weight Change
Wilfley DE et al. Presented at the Eating
Disorders Research Society Annual Meeting
Charleston, South Carolina November 20-22, 2002.
22
Intermittent Drug Therapy

23
Effect of Continuous and Intermittent Phentermine
Therapy on Body Weight
Munro JF et al. Brit Med J 1352, 1968.
24
Effect of Continuous vs Intermittent Sibutramine
Therapy on Body Weight
0
Placebo Intermittent sibutramine Continuous
sibutramine
-2
-4
Body Weight Change (kg)
-6
-8
Run-in period
-10
0
4
8
12
16
20
24
28
32
36
40
44
48
Time (wk)
Sibutramine dose 15 mg/d
Wirth and Krause. JAMA 20012861331.
25
Pharmacologic and Surgical Management of Obesity
in Primary Care A Clinical Practice Guideline
from the ACP
  • Ann Intern Med 2005142525-531.

26
Medications Used for Weight Loss
  • Phentermine
  • Diethylpropion
  • Sibutramine
  • Orlistat
  • Approved by the FDA for short term weight loss
  • Approved by the FDA for weight loss and weight
    maintenance

27
Off-label Use of Medications for Weight Loss
  • Bupropion
  • Fluoxetine
  • Sertraline
  • Topiramate
  • Zonisamide

28
Coverage of Weight Loss Medications
  • Typically not covered as a general rule
  • Although see 30 to 40 coverage
  • Typically covered medical conditions that get
    coverage of weight loss medications
  • Morbid obesity
  • With the threat of bariatric surgery
  • Diabetes
  • Patients with BMI of 35 with co-morbid
    condition
  • Metabolic syndrome

29
Paperwork Billing Codes
  • Very rarely covered by health insurances
  • Obesity 278.00
  • Usually paid billing codes
  • Morbid obesity 278.01
  • Dysmetabolic Syndrome 277.7
  • Impaired fasting glucose 790.21
  • Impaired GTT 790.22

30
ACP Guidelines
  • 5 recommendations based on the evidence report
    and accompanying background papers developed by
    the Southern California Evidence-Based Practice
    Center
  • The ACP recommends all clinicians refer to these
    guidelines as part of an overall strategy for
    managing overweight and obese patients
  • Overall strategy should always include
    appropriate diet and exercise
  • Target audience is patients with BMIs of above 30

31
ACP GuidelinesRecommendation 1
  • Clinicians should counsel all patients with a BMI
    above 30 on lifestyle and behavior modifications
    such as appropriate diet and exercise
  • Patient goals should be individually determined

32
ACP GuidelinesRecommendation 2
  • Pharmacologic therapy can be offered to patients
    who have failed diet and exercise alone
  • Doctor-patient discussion of side effects, long
    term safety data, and temporary nature of weight
    loss achieved with medications should occur
    before medication initiation

33
ACP GuidelinesRecommendation 3
  • Medication choices for the obese patient include
    sibutramine, orlistat, phentermine,
    diethylpropion, fluoxetine and bupropion
  • The choice of drug should be dependent on the
    side effect profile and the patients tolerance of
    the side effects

34
ACP GuidelinesRecommendation 4
  • Surgery should be considered as a treatment
    option for patients with a BMI over 40 who
  • Instituted but failed an adequate exercise and
    diet program (with or without adjunctive drug
    therapy)
  • AND
  • Present with obesity-related comorbid conditions
    such as hypertension, impaired glucose tolerance,
    diabetes mellitus, hyperlipidemia and obstructive
    sleep apnea
  • Doctor-patient discussion of surgery should
    include long term side effects

35
ACP GuidelinesRecommendation 5
  • Patients should be referred to high-volume
    centers with surgeons experienced in bariatric
    surgery

36
Bariatric Surgery
37
Recommendations for Patient Selection
  • Between ages 18 and 50
  • Stable preoperative weight for 3-5 years
  • Smoking cessation for at least 6 weeks
  • Those with psychiatric history require careful
    assessment
  • Tests to predict success of surgery
  • Personality factors
  • Eating habits
  • Motivation

Grace DM. Gastroenterol Clin North Am.
198716399.
38
Types of Surgery Gastric Bypass
  • Roux-en-Y gastric bypass is the most popular in
    the US
  • Pouch can be created with staples or complete
    division
  • Long-term weight loss of 50 of excess body
    weight
  • Moving Roux limbs distally creates more rapid
    weight loss
  • Malabsorption problems may be exacerbated

39
Types of Surgery Gastroplasty
  • Vertical banded gastroplasty now the preferred
    type of gastroplasty
  • Less enlargement over time
  • Produces weight loss, but usually less than
    gastric bypass

40
Types of Surgery Gastric Banding
  • Problems with original gastric band
  • Pouch too large or small
  • Adjustable gastric band developed in the 1980s
  • Controls restriction by injection/withdrawal of
    saline
  • May be performed laparoscopically

41
Mechanisms
  • Operations dramatically restrict gastric size,
    reducing nutritional intake
  • Some types of surgery decrease the absorption
    efficiency of nutrients
  • Roux-en-Y gastric bypass
  • Biliopancreatic diversion (BPD)
  • Malabsorption procedures create a greater risk
    for nutritional deficiencies

42
Side Effects Complications
1 in 200-300 patients in the US die from
bariatric surgery
  • Nausea
  • Vomiting
  • Abdominal pain
  • Constipation
  • Marginal ulceration
  • Gallstones
  • Bleeding ulcer
  • Obstruction of the stomach outlet
  • Iron deficiency
  • Vitamin B12 deficiency
  • Folic Acid deficiency
  • Dehydration
  • Vitamin A deficiency
  • Electrolyte deficiency
  • Protein deficiency
  • Hyperparathyroidism
  • Follow up of nutritional and metabolic problems
    after bariatric surgery K. Fujioka Diabetes Care
    28481-484,2005

Shikora SA. Nutrition in Clinical Practice.
20001513. www.mayoclinic.com. Surgery for
obesity What is it and is it for you?. Accessed
February 15, 2005.
Write a Comment
User Comments (0)
About PowerShow.com